Axovant Sciences Ltd. (AXON) EPS Estimated At $-0.49

January 23, 2018 - By Linda Rogers

 Axovant Sciences Ltd. (AXON) EPS Estimated At $ 0.49

Analysts expect Axovant Sciences Ltd. (NASDAQ:AXON) to report $-0.49 EPS on February, 13.They anticipate $0.01 EPS change or 2.08 % from last quarter’s $-0.48 EPS. After having $-0.64 EPS previously, Axovant Sciences Ltd.’s analysts see -23.44 % EPS growth. The stock increased 8.37% or $0.17 during the last trading session, reaching $2.2. About 3.03 million shares traded or 95.53% up from the average. Axovant Sciences Ltd. (NASDAQ:AXON) has risen 97.46% since January 23, 2017 and is uptrending. It has outperformed by 80.76% the S&P500.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. The company has market cap of $236.96 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. It currently has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Another recent and important Axovant Sciences Ltd. (NASDAQ:AXON) news was published by Reuters.com which published an article titled: “Axovant shares plunge after key drug program scrapped” on January 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.